Compare Stocks

Date Range: 

 AmgenNovavaxAstraZeneca
SymbolNASDAQ:AMGNNASDAQ:NVAXNASDAQ:AZN
Price Information
Current Price$250.65$170.81$53.32
52 Week RangeHoldBuyBuy
MarketRank™
Overall Score2.31.62.2
Analysis Score2.23.44.4
Community Score3.03.12.9
Dividend Score2.50.01.7
Ownership Score1.70.80.0
Earnings & Valuation Score1.90.61.9
Analyst Ratings
Consensus RecommendationHoldBuyBuy
Consensus Price Target$255.62$229.64$89.50
% Upside from Price Target1.98% upside34.44% upside67.85% upside
Trade Information
Market Cap$143.27 billion$12.72 billion$140.81 billion
Beta0.762.010.55
Average Volume2,724,9494,192,06910,885,304
Sales & Book Value
Annual Revenue$23.36 billion$18.66 million$24.38 billion
Price / Sales6.16678.215.74
Cashflow$19.31 per shareN/A$3.29 per share
Price / Cash12.98N/A16.21
Book Value$16.28 per share($5.75) per share$5.56 per share
Price / Book15.40-29.719.59
Profitability
Net Income$7.84 billion$-132,690,000.00$1.34 billion
EPS$14.82($5.80)$1.75
Trailing P/E Ratio20.21N/A55.54
Forward P/E Ratio14.749.6820.51
P/E Growth1.90N/A1.18
Net Margins29.42%-133.10%9.65%
Return on Equity (ROE)95.55%-1,346.17%37.23%
Return on Assets (ROA)15.52%-45.85%8.30%
Dividend
Annual Payout$7.04N/A$1.86
Dividend Yield2.81%N/A3.49%
Three-Year Dividend Growth39.13%N/AN/A
Payout Ratio47.50%N/A106.29%
Years of Consecutive Dividend Growth1 YearsN/AN/A
Debt
Debt-to-Equity Ratio3.12%3.61%1.34%
Current Ratio2.28%2.81%0.96%
Quick Ratio1.88%2.81%0.76%
Ownership Information
Institutional Ownership Percentage75.23%49.91%15.57%
Insider Ownership Percentage0.36%3.30%N/A
Miscellaneous
Employees24,30079276,100
Shares Outstanding574.55 million74.09 million2.62 billion
Next Earnings Date7/27/2021 (Estimated)5/10/2021 (Confirmed)7/29/2021 (Estimated)
OptionableOptionableOptionableOptionable
SourceHeadline
AstraZeneca (AZN) Confident Shareholders Back $39 Billion Alexion (ALXN) Deal - BloombergAstraZeneca (AZN) Confident Shareholders Back $39 Billion Alexion (ALXN) Deal - Bloomberg
bloomberg.com - May 6 at 2:15 PM
New Study Finds ‘Small’ Blood Clot Risk After One AstraZeneca Vaccine Dose, Rates Are Higher Than Expected For General Population - ForbesNew Study Finds ‘Small’ Blood Clot Risk After One AstraZeneca Vaccine Dose, Rates Are Higher Than Expected For General Population - Forbes
forbes.com - May 6 at 2:15 PM
On vaccinating the globe, Blinken warns: We have to speed this upOn vaccinating the globe, Blinken warns: 'We have to speed this up'
finance.yahoo.com - May 6 at 2:15 PM
UPDATE 1-Germany to allow AstraZeneca COVID-19 vaccine for all adultsUPDATE 1-Germany to allow AstraZeneca COVID-19 vaccine for all adults
finance.yahoo.com - May 6 at 2:15 PM
U.S. backing waiver of patent protection for vaccines is a ‘complex issue’: DoctorU.S. backing waiver of patent protection for vaccines is a ‘complex issue’: Doctor
finance.yahoo.com - May 6 at 2:15 PM
How the Moderna, AstraZeneca, Pfizer and other Covid vaccines compare - Telegraph.co.ukHow the Moderna, AstraZeneca, Pfizer and other Covid vaccines compare - Telegraph.co.uk
telegraph.co.uk - May 6 at 11:28 AM
UK regulator says some evidence AstraZeneca clots occur more in women than men - WTVB NewsUK regulator says some evidence AstraZeneca clots occur more in women than men - WTVB News
wtvbam.com - May 6 at 11:28 AM
Thromboembolism and the Oxford-AstraZeneca vaccine - The BMJThromboembolism and the Oxford-AstraZeneca vaccine - The BMJ
bmj.com - May 6 at 11:28 AM
Why is the EU Suing AstraZeneca? - Motley FoolWhy is the EU Suing AstraZeneca? - Motley Fool
fool.com - May 6 at 8:38 AM
Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination - The BMJ - The BMJThrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination - The BMJ - The BMJ
blogs.bmj.com - May 6 at 8:38 AM
Why is the EU Suing AstraZeneca?Why is the EU Suing AstraZeneca?
finance.yahoo.com - May 6 at 8:38 AM
Trudeau says he is glad he got AstraZeneca, vaccines are only way out of pandemic - Cranbrook TownsmanTrudeau says he is glad he got AstraZeneca, vaccines are only way out of pandemic - Cranbrook Townsman
cranbrooktownsman.com - May 6 at 3:37 AM
1 shot of Pfizer, AstraZeneca COVID-19 effective in South Korea - Business Insider1 shot of Pfizer, AstraZeneca COVID-19 effective in South Korea - Business Insider
businessinsider.com - May 6 at 3:37 AM
UPDATE 1-GAVI welcomes Biden move on vaccines, urges U.S. manufacturers to transfer know-howUPDATE 1-GAVI welcomes Biden move on vaccines, urges U.S. manufacturers to transfer know-how
finance.yahoo.com - May 6 at 3:37 AM
I got my first AstraZeneca shot. The only lasting effect has been a sense of relief - The GuardianI got my first AstraZeneca shot. The only lasting effect has been a sense of relief - The Guardian
theguardian.com - May 5 at 11:24 PM
President Biden to back waiving IP protections for COVID vaccinesPresident Biden to back waiving IP protections for COVID vaccines
finance.yahoo.com - May 5 at 6:24 PM
NACI is right about AstraZeneca. It shouldn’t be unsettling to trust the public with uncomfortable information - National PostNACI is right about AstraZeneca. It shouldn’t be 'unsettling' to trust the public with uncomfortable information - National Post
nationalpost.com - May 5 at 5:30 PM
Trudeau says he is glad he got AstraZeneca, vaccines are only way out of pandemic – Aldergrove Star - Aldergrove StarTrudeau says he is glad he got AstraZeneca, vaccines are only way out of pandemic – Aldergrove Star - Aldergrove Star
aldergrovestar.com - May 5 at 1:23 PM
Alchemab to Collaborate With AstraZeneca to Use Alchemabs Drug Discovery Platform for Prostate Cancer Study - BioSpaceAlchemab to Collaborate With AstraZeneca to Use Alchemab's Drug Discovery Platform for Prostate Cancer Study - BioSpace
biospace.com - May 5 at 12:30 PM
AstraZeneca investors hit back at CEO Soriots 2021 pay plan after COVID vaccine stumbles - FiercePharmaAstraZeneca investors hit back at CEO Soriot's 2021 pay plan after COVID vaccine stumbles - FiercePharma
fiercepharma.com - May 5 at 12:30 PM
Going to Court: The EU Sues AstraZeneca - International Policy DigestGoing to Court: The EU Sues AstraZeneca - International Policy Digest
intpolicydigest.org - May 5 at 12:30 PM
Alchemab And AstraZeneca Collaborate On Prostate Cancer ResearchAlchemab And AstraZeneca Collaborate On Prostate Cancer Research
finance.yahoo.com - May 5 at 12:30 PM
Malaysia imposes restrictions in capital as virus cases riseMalaysia imposes restrictions in capital as virus cases rise
finance.yahoo.com - May 5 at 8:22 AM
Alchemab to Collaborate With AstraZeneca to Use Alchemab’s Drug Discovery Platform for Prostate Cancer Study - Yahoo FinanceAlchemab to Collaborate With AstraZeneca to Use Alchemab’s Drug Discovery Platform for Prostate Cancer Study - Yahoo Finance
finance.yahoo.com - May 5 at 7:29 AM
AstraZeneca And Pfizer Covid-19 Vaccines More Than 86% Effective After First Dose, South Korean Authorities Say - ForbesAstraZeneca And Pfizer Covid-19 Vaccines More Than 86% Effective After First Dose, South Korean Authorities Say - Forbes
forbes.com - May 5 at 7:29 AM
Are These Covid Treatment Makers Getting A Price Booster Shot? (AZN)Are These Covid Treatment Makers Getting A Price Booster Shot? (AZN)
marketbeat.com - April 20 at 4:59 PM
AstraZeneca (NASDAQ:AZN) Stock Rating Reaffirmed by ArgusAstraZeneca (NASDAQ:AZN) Stock Rating Reaffirmed by Argus
marketbeat.com - April 19 at 8:49 AM
3 Big-Time Biotech Stocks to Buy Now (AZN)3 Big-Time Biotech Stocks to Buy Now (AZN)
marketbeat.com - April 2 at 8:22 AM
Time to Sell the News on Moderna (NASDAQ: MRNA) Stock  (AZN)Time to Sell the News on Moderna (NASDAQ: MRNA) Stock (AZN)
marketbeat.com - December 28 at 9:22 AM
Moderna (NASDAQ:MRNA) Makes Explosive Gains in Pre-Market (AZN)Moderna (NASDAQ:MRNA) Makes Explosive Gains in Pre-Market (AZN)
marketbeat.com - November 30 at 11:15 AM
How to Invest After a Turbulent 2020 Election (AZN)How to Invest After a Turbulent 2020 Election (AZN)
marketbeat.com - November 23 at 5:51 PM
DateCompanyBrokerageAction
5/4/2021AmgenRoyal Bank of CanadaLower Price Target
5/4/2021AmgenCredit Suisse GroupLower Price Target
5/4/2021AmgenSVB LeerinkLower Price Target
5/4/2021AmgenAtlantic SecuritiesReiterated Rating
5/3/2021AmgenOppenheimerLower Price Target
5/3/2021AmgenMorgan StanleyLower Price Target
4/29/2021AmgenRobert W. BairdReiterated Rating
4/29/2021AmgenEvercore ISIReiterated Rating
4/28/2021AmgenJPMorgan Chase & Co.Reiterated Rating
4/28/2021AmgenThe Goldman Sachs GroupReiterated Rating
4/28/2021AmgenBMO Capital MarketsLower Price Target
3/11/2021AmgenBarclaysLower Price Target
3/18/2021NovavaxHC WainwrightBoost Price Target
2/5/2021NovavaxCantor FitzgeraldBoost Price Target
2/1/2021NovavaxB. RileyBoost Price Target
12/14/2020NovavaxJefferies Financial GroupInitiated Coverage
8/5/2020NovavaxLADENBURG THALM/SH SHDowngrade
4/19/2021AstraZenecaArgusReiterated Rating
3/23/2021AstraZenecaSociete GeneraleReiterated Rating
3/18/2021AstraZenecaDeutsche Bank AktiengesellschaftReiterated Rating
3/9/2021AstraZenecaBerenberg BankReiterated Rating
3/3/2021AstraZenecaUBS GroupUpgrade
12/30/2020AstraZenecaAlphaValueUpgrade
12/13/2020AstraZenecaPiper SandlerLower Price Target
11/11/2020AstraZenecaHSBCUpgrade
9/23/2020AstraZenecaOddo BhfUpgrade
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.